Natixis Advisors LLC boosted its holdings in shares of MetLife, Inc. (NYSE:MET - Free Report) by 4.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 302,575 shares of the financial services provider's stock after buying an additional 12,445 shares during the quarter. Natixis Advisors LLC's holdings in MetLife were worth $24,294,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD increased its holdings in MetLife by 33.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 24,663,239 shares of the financial services provider's stock valued at $2,019,427,000 after buying an additional 6,213,923 shares during the period. Bank of New York Mellon Corp increased its holdings in MetLife by 0.4% during the first quarter. Bank of New York Mellon Corp now owns 8,862,835 shares of the financial services provider's stock valued at $711,597,000 after buying an additional 36,177 shares during the period. Northern Trust Corp increased its holdings in MetLife by 15.7% during the fourth quarter. Northern Trust Corp now owns 7,052,202 shares of the financial services provider's stock valued at $577,434,000 after buying an additional 958,458 shares during the period. Dimensional Fund Advisors LP boosted its stake in MetLife by 4.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 6,434,737 shares of the financial services provider's stock valued at $526,869,000 after acquiring an additional 290,734 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in MetLife by 12.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,113,108 shares of the financial services provider's stock valued at $418,661,000 after acquiring an additional 564,383 shares in the last quarter. 94.99% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities research analysts have weighed in on MET shares. JPMorgan Chase & Co. raised their target price on shares of MetLife from $86.00 to $95.00 and gave the company an "overweight" rating in a research note on Tuesday, July 8th. Keefe, Bruyette & Woods lowered their target price on shares of MetLife from $95.00 to $94.00 and set an "outperform" rating for the company in a research note on Wednesday, July 9th. Barclays raised their target price on shares of MetLife from $88.00 to $94.00 and gave the company an "overweight" rating in a research note on Monday, July 7th. Wall Street Zen downgraded shares of MetLife from a "buy" rating to a "hold" rating in a research note on Saturday, May 24th. Finally, Wells Fargo & Company restated an "overweight" rating and issued a $97.00 target price (up from $94.00) on shares of MetLife in a research note on Thursday, July 10th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $96.10.
Read Our Latest Report on MET
MetLife Stock Down 2.6%
MET stock opened at $74.00 on Friday. The stock has a market capitalization of $49.68 billion, a P/E ratio of 12.03, a P/E/G ratio of 0.62 and a beta of 0.85. The firm has a 50-day simple moving average of $78.40 and a 200-day simple moving average of $79.48. The company has a quick ratio of 0.16, a current ratio of 0.16 and a debt-to-equity ratio of 0.55. MetLife, Inc. has a 52 week low of $65.21 and a 52 week high of $89.05.
MetLife (NYSE:MET - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The financial services provider reported $1.96 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.00 by ($0.04). MetLife had a net margin of 6.08% and a return on equity of 20.89%. The business had revenue of $18.57 billion for the quarter, compared to analysts' expectations of $18.06 billion. During the same period in the prior year, the company posted $1.83 EPS. The firm's revenue was up 15.6% on a year-over-year basis. Equities analysts forecast that MetLife, Inc. will post 9.65 earnings per share for the current fiscal year.
MetLife announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, April 30th that allows the company to buyback $3.00 billion in shares. This buyback authorization allows the financial services provider to buy up to 5.9% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's management believes its shares are undervalued.
MetLife Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 5th will be paid a dividend of $0.5675 per share. This represents a $2.27 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Tuesday, August 5th. MetLife's dividend payout ratio is currently 36.91%.
MetLife Profile
(
Free Report)
MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MetLife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MetLife wasn't on the list.
While MetLife currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.